One of the best ways to diversify your portfolio in any sector is with an ETF.
Not only does it offer investors diversification, it does so at less cost.
For example, look at the iShares NASDAQ Biotech ETF (IBB). Some of its top holdings include Amgen, Vertex, Gilead, Illumina, Moderna, Biogen, and dozens more. If you were to buy 10 shares of each stock listed, it’d cost you thousands of dollars.
Not only does the IBB give you the same exposure, it does so at just $163.
Horizon’s Psychedelic ETF
It’s part of the reason you should pay close attention to the new Horizons Psychedelic ETF, which is expected to start trading on Jan. 26.
The ETF is expected to list as PSYK on the NEO exchange.
“The ETF includes companies in the Canadian legal psychedelics industry, as well as U.S. companies engaged in legal activities involving psychedelic drugs and substances. The purpose of the ETF is to ‘invest in, and indirectly derive revenues from, companies in the psychedelics industry engaged in legal activities involving psychedelic drugs and substances,’” as noted in a recent press release from Mind Cure Health.
While some may not have an interest in the psychedelics industry, they may want to rethink that. Not only is the US FDA supportive of research, but we’re seeing major studies on psilocybin success for anxiety and depression, for example. Johns Hopkins University and New York University are studying such treatments, as well.
In addition, “By the end of 2021, I expect the conversation about access to therapeutic outcomes using what were previously known as psychedelics to be a global conversation,” said Bruce Linton, former CEO and founder of Canopy Growth, as quoted by Benzinga.
Plus, it wouldn’t be a shock to see big pharmaceuticals taking an interest in psychedelics. If they can successfully help with mental health issues, such drugs could bring in billions.
Some of the stocks likely to list on the new ETF could see higher highs, too. Some of the top companies that could list on the ETF include Compass Pathways, Mind Med, Field Trip Health, Revive Therapeutics, Cybin, and Mind Cure Health.